Hydroxychloroquine in systemic lupus erythematosus: Results of a French multicentre controlled trial (PLUS Study)

Annals of the Rheumatic Diseases

Volumn 72, Issue 11, 2013, Pages 1786-1792

  Costedoat Chalumeau, Nathalie ^a,b   Galicier, Lionel ^c,d   Aumaître, Olivier ^e,f   Francès, Camille ^a,g   Guern, Véronique Le ^c,h   Lioté, Frédéric ^c,i   Smail, Amar ^j   Limal, Nicolas ^k   Perard, Laurent ^l   Desmurs Clavel, Hélène ^l   Boutin, Du Le Thi Huong ^b   Asli, Bouchra ^d   Kahn, Jean Emmanuel ^m   Pourrat, Jacques ^n,o   Sailler, Laurent ^n,p   Ackermann, Félix ^m   Papo, Thomas ^c,q   Sacré, Karim ^c,q   Fain, Olivier ^r,s   Stirnemann, Jerome ^r,s   Cacoub, Patrice ^a,b,t,u   Jallouli, Moez ^b   Leroux, Gaelle ^b   Cohen Bittan, Judith ^b   Tanguy, Marie Laure ^b   Hulot, Jean Sébastien ^a,b   Lechat, Philippe ^a,b   Musset, Lucile ^b   Amoura, Zahir ^a,b   Piette, Jean Charles ^a,b   more..

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e UNIVERSITÉ CLERMONT AUVERGNE   (France)

^f SERVICE DE RHUMATOLOGIE   (France)

^g HÔPITAL TENON   (France)

^h Université Paris Decartes ^*  (France)

ⁱ HÔPITAL LARIBOISIÈRE   (France)

^j AMIENS UNIVERSITY HOSPITAL   (France)

^k HENRI MONDOR HOSPITAL   (France)

^l HOSPICES CIVILS DE LYON   (France)

^m FOCH HOSPITAL   (France)

ⁿ UNIVERSITÉ DE TOULOUSE   (France)

^o CHU RANGUEIL   (France)

^p CHU PURPAN   (France)

^q BICHAT HOSPITAL   (France)

^r UNIVERSITÉ PARIS 13   (France)

^s HÔPITAL JEAN VERDIER   (France)

^t Unit of Dermatology   (France)

^u CNRS   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE; PLACEBO; PREDNISONE;

ADULT; ARTICLE; BLURRED VISION; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; FEMALE; FOLLOW UP; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

PHARMACOKINETICS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT;

ADULT; ANTIRHEUMATIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; FRANCE; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84881322752     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202322     Document Type: Article

References (23)

1. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358:929-39.
2. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 2003;82:299-308.
3. Costedoat-Chalumeau N, Amoura Z, Hulot JS, et al. Hydroxychloroquine in systemic lupus erythematosus. Lancet 2007;369:1257-8.
4. Costedoat-Chalumeau N, Leroux G, Piette J-C, et al. Antimalarials and systemic lupus erythematosus. In: Lahita RG, Tsokos G, Buyon JP, Koike T. Systemic lupus erythematosus. 5th edn. London: Elsevier, 2010:1061-81.
5. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010;69:20-8.
6. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991;324:150-4.
7. Shinjo SK, Bonfa E, Wojdyla D, et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 2010;62:855-62.
8. Munster T, Gibbs JP, Shen D, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 2002;46:1460-9.
9. Tett SE, Cutler DJ, Beck C, et al. Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis-a prospective, dose ranging study. J Rheumatol 2000;27:1656-60.
10. Frances C, Cosnes A, Duhaut P, et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol 2012;148:479-84.
11. Costedoat-Chalumeau N, Amoura Z, Hulot JS, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:3284-90.
12. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
13. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-8.
14. Costedoat-Chalumeau N, Amoura Z, Hulot JS, et al. Very low blood Hydroxychloroquine concentrations as an objective marker of poor adherence to treatment in systemic lupus erythematosus. Ann Rheum Dis 2007;66:821-4.
15. Ting TV, Kudalkar D, Nelson S, et al. Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus. J Rheumatol 2012;39:174-9.
16. Briesacher BA, Andrade SE, Fouayzi H, et al. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008;28:437-43.
17. Isenberg DA, Allen E, Farewell V, et al. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis 2011;70:54-9.
18. Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 2010;115:2292-9.
19. Lafyatis R, York M, Marshak-Rothstein A. Antimalarial agents: closing the gate on toll-like receptors? Arthritis Rheum 2006;54:3068-70.
20. Yang ZJ, Chee CE, Huang S, et al. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 2011;10:1533-41.
21. Sotelo J, Briceno E, Lopez-Gonzalez MA. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006;144:337-43.
22. Swampillai AL, Salomoni P, Short SC. The role of autophagy in clinical practice. Clin Oncol (R Coll Radiol) 2012;24:387-95.
23. Rosenfeld MR, Grossman SA, Brem S, et al. Pharmacokinetic analysis and pharmacodynamic evidence of autophagy inhibition in patients with newly diagnosed glioblastoma treated on a phase I trial of hydroxychloroquine in combination with temozolomide and radiation. J Clin Oncol 2010;28: 15s (suppl; abstr 3086).